Factory 99% Milrinone Powder CAS 78415-72-2 Chemical Intermediate Milrinone

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A750
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Milrinone
• CAS: 78415-72-2
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 1g
• Function: Chemical Intermediate
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

 

Product Name	Milrinone
Appearance	White Powder
CAS NO.	78415-72-2
Storage	Keep in a cool, dry, dark location

 

Milrinone is a phosphodiesterase inhibitor that belongs to the class of inotropic agents. It is specifically a pyridazinone derivative with positive inotropic and vasodilator properties.

 

1. Cardiovascular Diseases: Milrinone is primarily used in the treatment of cardiovascular diseases, particularly in cases where conventional therapies have failed or are ineffective.
2. Short-term Therapy: It is indicated for short-term intravenous infusion in patients with decompensated heart failure to improve hemodynamic status.
3. Post-operative Care: Milrinone may also be used in the post-operative setting to support cardiac function following surgical procedures.

1. Inotropic Effect: By inhibiting phosphodiesterase III, Milrinone increases the concentration of cyclic adenosine monophosphate (cAMP) within myocardial cells. This leads to an enhancement of myocardial contractility and an increase in cardiac output.
2. Vasodilator Effect: The increased cAMP levels also cause relaxation of vascular smooth muscle, resulting in vasodilation and a reduction in systemic vascular resistance. This helps to decrease afterload and improve cardiac function.
3. Anti-platelet Aggregation: Milrinone has also been shown to inhibit platelet aggregation, which may contribute to its anti-thrombotic effects and further benefit patients with cardiovascular disease.